Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment

BACKGROUND: Chronic myeloid leukemia (CML) treatment is lifelong, and while it is important for patients to remain adherent to treatment, there are conflicting findings with respect to differences in adherence and persistence with dasatinib or nilotinib during second-line treatment. OBJECTIVES: To c...

Descripción completa

Detalles Bibliográficos
Autores principales: Trivedi, Digisha, Landsman-Blumberg, Pamela, Darkow, Theodore, Smith, David, McMorrow, Donna, Mullins, C. Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441018/
https://www.ncbi.nlm.nih.gov/pubmed/25278323
http://dx.doi.org/10.18553/jmcp.2014.20.10.1006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441018/
https://www.ncbi.nlm.nih.gov/pubmed/25278323
http://dx.doi.org/10.18553/jmcp.2014.20.10.1006

Ejemplares similares